Patents by Inventor Kevin Brindle

Kevin Brindle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Restraint for securing a person to an object, and a cut-resistant webbing
    Patent number: 11911308
    Abstract: A non-injurious restraint for securing a person to an object comprising a flexible strap comprised of, or including a substantially cut-resistant webbing associated with a strip of steel interlinked rings and reinforcement cables. A locking mechanism including one or more projections or pins adapted to engage the interlinked rings in forming a fixed length loop. The strap adapted to be secured to the object with the loop adjusted to encircle the limb, and wherein the locking mechanism locks the length of the loop. A webbing for use in such restraints.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: February 27, 2024
    Assignee: The Crown in right of the State of New South Wales acting through the Department of Justice Corrective Services NSW, Corrective Services Industries
    Inventors: Stephen John Thorpe, Kevin Desmond Corcoran, Derek Brindle, George Semertzidis
  • Hyperpolarized lactate contrast agent for determination of LDH activity
    Patent number: 9408925
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarized [13C, 2H] lactate.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 9, 2016
    Assignee: General Electric Company
    Inventors: Kevin Brindle, Mikko Kettunen, Brett Kennedy
  • HYPERPOLARIZED LACTATE CONTRAST AGENT FOR DETERMINATION OF LDH ACTIVITY
    Publication number: 20160184462
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarised [13C, 2H] lactate.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 30, 2016
    Inventors: Kevin Brindle, Mikko Kettunen, Brett Kennedy
  • Hyperpolarized lactate contrast agent for determination of LDH activity
    Patent number: 9259490
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarized [13C, 2H]lactate.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: February 16, 2016
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Kevin Brindle, Mikko Iivari Kettunen, Brett W.C. Kennedy
  • Agents for detecting and imaging cell death
    Patent number: 8685371
    Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumors following cancer treatment.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: April 1, 2014
    Assignee: Cambridge Enterprise Limited
    Inventors: Kevin Brindle, Andre Neves, Maaike De Backer, Israt Alam
  • HYPERPOLARIZED LACTATE CONTRAST AGENT FOR DETERMINATION OF LDH ACTIVITY
    Publication number: 20130052141
    Abstract: A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarised [13C, 2H]lactate.
    Type: Application
    Filed: May 2, 2011
    Publication date: February 28, 2013
    Applicant: GE HEALTHCARE LIMITED
    Inventors: Kevin Brindle, Mikko Iivari Kettunen, Brett W.C. Kennedy
  • AGENTS FOR DETECTING AND IMAGING CELL DEATH
    Publication number: 20110038798
    Abstract: This invention relates to molecular imaging agents comprising an S78C mutant synaptotagmin I C2A domain. These agents may be useful in detecting or assessing cell death in vitro and in vivo, for example in tumours following cancer treatment.
    Type: Application
    Filed: April 29, 2009
    Publication date: February 17, 2011
    Applicant: Cambridge Enterprise Limited
    Inventors: Kevin Brindle, Andre Neves, Maaike De Backer, Israt Alam